Loading, Please Wait...
SALT LAKE CITY, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB: NUMD), a medical device leader developing new nitric oxide delivery technology will receive its first clinical unit prototype and begin testing to verify design parameters. The Nu-Med Plus clinical unit is designed to provide clinicians and care providers several key competitive advantages.
The small unit fits easily into medical offices, emergency departments and nursing homes, and offers a touchscreen for ease-of-use and precision single-dose control. The clinical unit utilizes either a proprietary formula of nitric oxide generation or prefilled nitric oxide canisters.
“The clinical unit multiplies the number of markets Nu-Med Plus is able to serve with our technology,” Nu-Med Plus CEO Jeff Robins stated, “The market-leading innovation offers providers and patients new treatment options, in new convenient environments, to address health issues that significantly impact quality of life and cost billions of dollars annually to treat.”
The unit is engineered to provide treatment for multiple therapeutic needs such as high blood pressure, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), and other conditions benefiting from vasodilation and increased delivery of oxygen to diseased and injured tissue.
When delivered in precise doses, inhaled nitric oxide has already been proven to stabilize blood pressure, open airways, fight infections and blood clots, treat erectile dysfunction and combat signs of aging.
Nu-Med Plus is currently in the process of FDA approval for three nitric oxide delivery units including a fixed hospital unit, clinical unit, and a portable unit. Nu-Med Plus’s technology is designed to be utilized for a variety of inhaled nitric oxide treatments. For more information please visit www.nu-medplus.com. Follow Nu-Med Plus on Twitter and LinkedIn for the latest news.
Media Contact: email@example.com
About Nu-Med Plus, Inc.: Nu-Med Plus, Inc. founded in 2011, is a medical device development company created to explore medical applications of newly developed nitric oxide technologies. The strategy focuses on high growth-potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use.
Forward-Looking Statements: Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8f189352-9b06-414a-a52a-ed091cd0fe60